Parkman Healthcare Partners LLC Sells 71,167 Shares of uniQure N.V. $QURE

Key Points

• Parkman Healthcare Partners LLC reduced its stake in uniQure N.V. by 25.9%, selling 71,167 shares and retaining 203,833 shares worth approximately $2.16 million.
• Several hedge funds acquired new stakes in uniQure or increased their holdings, with institutional investors now owning 78.83% of the company's stock.
• Analysts have set various target prices for uniQure shares, with a consensus average target price of $37.45 and a majority rating the stock as a Buy.

Parkman Healthcare Partners LLC decreased its stake in uniQure N.V. (NASDAQ:QURE - Free Report) by 25.9% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 203,833 shares of the biotechnology company's stock after selling 71,167 shares during the period. Parkman Healthcare Partners LLC owned 0.37% of uniQure worth $2,161,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of QURE. Mraz Amerine & Associates Inc. acquired a new stake in uniQure in the 1st quarter valued at about $106,000. OMERS ADMINISTRATION Corp acquired a new stake in uniQure in the 1st quarter valued at about $152,000. Wells Fargo & Company MN lifted its stake in uniQure by 13.9% in the 4th quarter. Wells Fargo & Company MN now owns 12,294 shares of the biotechnology company's stock valued at $217,000 after purchasing an additional 1,503 shares during the last quarter. XTX Topco Ltd lifted its stake in uniQure by 127.3% in the 1st quarter. XTX Topco Ltd now owns 36,999 shares of the biotechnology company's stock valued at $392,000 after purchasing an additional 20,720 shares during the last quarter. Finally, Lighthouse Investment Partners LLC acquired a new stake in uniQure in the 4th quarter valued at about $397,000. Institutional investors own 78.83% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the stock. Mizuho upgraded shares of uniQure from a "neutral" rating to an "outperform" rating and set a $30.00 target price for the company in a research note on Thursday, August 14th. Cantor Fitzgerald set a $47.00 target price on shares of uniQure in a research note on Wednesday, July 30th. HC Wainwright restated a "buy" rating and set a $70.00 price objective on shares of uniQure in a research report on Friday. Chardan Capital restated a "buy" rating and set a $35.00 price objective on shares of uniQure in a research report on Friday, August 29th. Finally, Guggenheim restated a "buy" rating and set a $28.00 price objective on shares of uniQure in a research report on Monday, May 12th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and two have assigned a Hold rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Buy" and an average target price of $37.45.

Insiders Place Their Bets

In related news, Director Rachelle Suzanne Jacques sold 2,112 shares of uniQure stock in a transaction that occurred on Friday, June 20th. The shares were sold at an average price of $14.45, for a total value of $30,518.40. Following the transaction, the director directly owned 28,346 shares of the company's stock, valued at $409,599.70. This trade represents a 6.93% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Madhavan Balachandran sold 2,112 shares of uniQure stock in a transaction that occurred on Friday, June 20th. The shares were sold at an average price of $14.45, for a total transaction of $30,518.40. Following the completion of the transaction, the director directly owned 37,697 shares in the company, valued at $544,721.65. This trade represents a 5.31% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 22,144 shares of company stock valued at $322,426 over the last three months. 4.79% of the stock is owned by corporate insiders.

uniQure Stock Up 1.2%

NASDAQ QURE opened at $17.95 on Friday. The company has a current ratio of 9.98, a quick ratio of 9.98 and a debt-to-equity ratio of 1.53. uniQure N.V. has a 1-year low of $4.45 and a 1-year high of $19.18. The company has a 50 day moving average of $14.98 and a 200-day moving average of $13.80. The company has a market cap of $984.92 million, a price-to-earnings ratio of -4.58 and a beta of 0.14.

uniQure (NASDAQ:QURE - Get Free Report) last released its quarterly earnings results on Tuesday, July 29th. The biotechnology company reported ($0.69) earnings per share for the quarter, beating analysts' consensus estimates of ($0.89) by $0.20. The company had revenue of $5.26 million during the quarter, compared to the consensus estimate of $5.00 million. uniQure had a negative net margin of 1,387.98% and a negative return on equity of 1,010.74%. On average, equities research analysts expect that uniQure N.V. will post -3.75 earnings per share for the current fiscal year.

uniQure Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.